Similar heart failure hospitalization and survival benefits are associated with Sacubitril/Valsartan therapy in CRT non responders and in HFrEF patients with no CRT indication
Event:
ESC Congress 2023
Topic:
Pharmacotherapy
Session:
Clinical heart failure from diagnostics to treatment
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/4252x1496/43d16b540f/ehra-acronym-name-rgb.png)
